Quantum-banner

Learn about a clinical trial for AML

Because every moment matters.

If you have been newly diagnosed with acute myeloid leukemia (AML), the QuANTUM-First Study may be an option for you. The study is evaluating an investigational medication for AML, given in addition to chemotherapy.

Treatment Sequence

Induction

(up to 2 cycles)


GOAL: Reduce cancer cells

Consolidation

(up to 4 cycles of chemotherapy, transplant allowed)


GOAL: Further reduce cancer cells

Maintenance

(up to 12 cycles)


GOAL: Maintain remission and prevent relapse

Participating in the QuANTUM-First Study will not interfere with your ability to receive a stem cell transplant.

Do I Qualify?

I have AML. Am I eligible for the QuANTUM-First Study?

You may qualify to participate in the study if:
  • You are between 18-75 years of age
  • You have been diagnosed with AML, and
  • Your test results come back positive for the FLT3-ITD genetic mutation
    • It’s likely that you’ll find this out during the first few days of your initial chemotherapy treatment (also known as induction chemotherapy)

Talk to your doctor and loved ones if you are interested in the QuANTUM-First Study. Your doctor can give you more information about the clinical trial and help you decide if it’s right for you.

Participating in the QuANTUM-First Study will not delay the start of your chemotherapy treatment.

About AML & FLT3-ITD

What is AML with FLT3-ITD?

Acute myeloid leukemia (AML) is a type of cancer that begins in the bone marrow and moves into the bloodstream.

AML is usually fast growing and needs to be treated quickly. Your doctor may have already performed blood and bone marrow tests to determine the type of AML you have, as well as any changes or mutations in your genes.

In some people, having a genetic mutation known as FLT3-ITD makes the disease more difficult to treat and relapse more likely. However, new drugs that target the FLT3-ITD mutation are currently being developed through clinical trials.

The National Comprehensive Cancer Network (NCCN) recommends that you speak with your physician to see if a clinical trial may be right for you.1

For additional information about clinical trials, please see http://www.cancer.gov/about-cancer/treatment/clinical-trials

  • Reference: 1. Panel chair, et. al., NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 1.2015. © 2014 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed February 4, 2016.

  • What happens to my personal information?

    Your personal information will not be shared with anyone who is not directly associated with this research program without your permission (except as required by law).

  • Who oversees clinical trials?

    To help ensure that a clinical trial is ethical and that volunteers’ rights are protected, Institutional Review Boards (IRB) or Ethics Committees (EC) review and approve study protocols.

  • Who can participate in a clinical trial?

    You must meet all of the study eligibility criteria in order to take part. To see if you qualify, the study team will review your medical history and evaluate your current medical status.

Contact a QuANTUM-First Study Site

For more information or to see if you may qualify for the QuANTUM-First Study, please contact a study site.

Study sites currently enrolling patients

Distance

ajax loader